We recently published a list of 10 Value Stocks in Ken Fisher’s Portfolio. In this article, we are going to take a look at ...

The stock's rise snapped a three-day losing streak.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

Shares of Merck & Co. Inc. MRK slid 2.46% to $76.46 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.